Stephen F. Betz, Chief Scientific Officer at Crinetics Pharmaceuticals, Inc. (CRNX), sold 194,966 shares at $32.23 ($6.3M) on 2025-06-12, disclosed to the SEC on 2025-06-16.
Scheduled sale ($6.3M) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $32.23 | 97,483 | $3.1M | 50.0% |
| 2 | $32.23 | 97,483 | $3.1M | 50.0% |
| Total | $32.23 avg | 194,966 | $6.3M | 100% |
| Filing → |
| CRNX | SELL | 2024-09-12 | $107K | — | Filing → |
| CRNX | SELL | 2024-08-28 | $160K | — | Filing → |
| CRNX | SELL | 2024-08-14 | $143K | — | Filing → |